European shares closed lower on Friday, with automakers among top decliners as investors grew skittish on worries of a global ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans for regulatory filing this year.

Global stocks steadied on Friday ahead of key U.S. payrolls data, with investors cautiously optimistic that the world might ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds ...

The company plans to allocate a record amount to capital expenditures to build artificial-intelligence infrastructure. The company expects bookings of between $5.55 billion to $5.65 billion for the ...

NEW YORK/SINGAPORE (Reuters) -Asia shares rose on Thursday, tracking gains on Wall Street following a see-saw session, while ...